课题基金 / 基金详情

项目摘要

项目成果

Mark Talan的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The broad objective of this program is to perform preclinical experimentation on the mouse genetic models of VEDS to test the efficacy of different therapeutic modalities to attenuate the vascular fragility and, thus, to prevent or to reduce the risk of vascular complications. With repect to specific steps outlined in Objectives, this year we concentrated on steps I and III. Characterization of existing genetic model of VEDS The haploinsufficiency for one COL3A1 allele is one of the genotypes resulting in VEDS. Homozygous Col3a1 mice, the only currently available and described model of VEDS, cannot be used for experiments due to extremely high prenatal mortality. We hypothesized, that heterozygous Col3a1 mice, originally described as phenotypically normal, can serve as an experimental model of haploinsufficiency. We compared aortas and colons of 9, 14 and 21 months old (+/-) and (+/+) Col3a1 mice in vivo (high frequency sonography and pressure-volume analyses) and ex vivo (histology and biomechanical properties). In all ages the aorta in +/- mice had a lower compliance, larger lumen diameter, and lower ex vivo rupture pressure, than in wild type mice. Histological evaluation of aortas of +/- mice demonstrated abnormalities among 100% of male and 50% of female mice, revealing elastin fragmentation, spindle cell proliferation, inflammation, and reactive fibrosis. The colon of +/- animals had higher compliance and lower maximal (pre-rupture) pressure (higher fragility) in 9-21 months old animals. This was associated with a lower collagen III content detected by quantitative RT-PCR and, on protein level, with peptides separated by HPLC and detected with LC-MS. Thus, the +/- Col3A1 mouse could serve as an experimental model for the VEDS. Development of molecular genetic tools to suppress specific mutations in tissue culture experiments The experiments conducted during this year led to a patent application, which is currently being filed, and thus cannot be disclosed at this time.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Behavioral, dietary and pharmacological modalities of cardioprotection
  • 批准号:
    7964069
  • 项目类别:
  • 资助金额:
    $19.2万
  • 财政年份:
    --
  • 负责人:
    Mark Talan
  • 依托单位:
Different Therapeutic Approaches forTreatment of Chronic Heart Failure
  • 批准号:
    7964059
  • 项目类别:
  • 资助金额:
    $42.02万
  • 财政年份:
    --
  • 负责人:
    Mark Talan
  • 依托单位:
Reduction of myocardial damage during acute ischemia
  • 批准号:
    8552489
  • 项目类别:
  • 资助金额:
    $34.89万
  • 财政年份:
    --
  • 负责人:
    Mark Talan
  • 依托单位:
Reduction of myocardial damage during acute ischemia
  • 批准号:
    7732335
  • 项目类别:
  • 资助金额:
    $7.59万
  • 财政年份:
    --
  • 负责人:
    Mark Talan
  • 依托单位:
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    雷芬芳
  • 依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    万荣
  • 依托单位: